Luoma Jason, Lear M Kati
Portland Psychotherapy Clinic, Research, and Training Center, Portland, OR, United States.
Front Psychiatry. 2021 Sep 27;12:733893. doi: 10.3389/fpsyt.2021.733893. eCollection 2021.
Social anxiety disorder (SAD) is a prevalent and often debilitating psychiatric disorder that can assume a chronic course even when treated. Despite the identification of evidence-based pharmacological and behavioral treatments for SAD, much room for improved outcomes exists and 3,4-methylenedioxymethamphetamine (MDMA) has been proposed as a promising adjunctive treatment to psychological interventions for disorders characterized by social dysfunction. A small randomized, placebo-controlled trial of MDMA-assisted therapy (MDMA-AT) for social anxiety in autistic adults offered encouraging results, but more research is sorely needed to explore the potential for MDMA-AT in treating SAD. This review aims to stimulate future study by summarizing research on disruptions in neurological, perceptual, receptive, and expressive systems regulating social behavior in SAD and proposing how MDMA-AT may alter these systems across four domains. First, we review research highlighting the roles of social anhedonia and reduced social reward sensitivity in maintaining SAD, with specific attention to the reduction in positive affect in social situations, infrequent social approach behaviors, and related social skills deficits. We posit that MDMA-AT may enhance motivation to connect with others and alter perceptions of social reward for an extended period following administration, thereby potentiating extinction processes, and increasing the reinforcement value of social interactions. Second, we review evidence for the central role of heightened social evaluative threat perception in the development and maintenance of SAD and consider how MDMA-AT may enhance experiences of affiliation and safety when interacting with others. Third, we consider the influence of shame and the rigid application of shame regulation strategies as important intrapersonal processes maintaining SAD and propose the generation of self-transcendent emotions during MDMA sessions as a mechanism of shame reduction that may result in corrective emotional experiences and boost memory reconsolidation. Finally, we review research on the role of dysfunctional interpersonal behaviors in SAD that interfere with social functioning and, in particular, the development and maintenance of close and secure relationships. We discuss the hypothesized role of MDMA-AT in improving social skills to elicit positive interpersonal responses from others, creating a greater sense of belonging, acceptance, and social efficacy.
社交焦虑障碍(SAD)是一种常见且往往使人衰弱的精神疾病,即使经过治疗也可能呈慢性病程。尽管已确定了针对SAD的循证药物和行为疗法,但改善治疗效果仍有很大空间,3,4-亚甲基二氧基甲基苯丙胺(摇头丸)已被提议作为一种有前景的辅助治疗方法,用于治疗以社交功能障碍为特征的疾病的心理干预。一项针对自闭症成年人社交焦虑的摇头丸辅助治疗(MDMA-AT)的小型随机安慰剂对照试验取得了令人鼓舞的结果,但迫切需要更多研究来探索MDMA-AT治疗SAD的潜力。本综述旨在通过总结关于调节SAD中社交行为的神经、感知、接受和表达系统紊乱的研究,并提出MDMA-AT如何在四个领域改变这些系统,来激发未来的研究。首先,我们回顾了强调社交快感缺失和社交奖励敏感性降低在维持SAD中的作用的研究,特别关注社交情境中积极情绪的减少、不频繁的社交接近行为以及相关社交技能缺陷。我们认为,MDMA-AT可能会增强与他人建立联系的动机,并在给药后的较长时间内改变对社交奖励的认知,从而增强消退过程,并增加社交互动中的强化价值。其次,我们回顾了关于社交评价威胁感知增强在SAD的发展和维持中的核心作用的证据,并考虑MDMA-AT如何在与他人互动时增强归属感和安全感。第三,我们考虑羞耻感的影响以及羞耻调节策略的严格应用作为维持SAD的重要人际内过程,并提出在MDMA治疗期间产生自我超越情绪作为减少羞耻感的一种机制,这可能会导致纠正性情绪体验并促进记忆重新巩固。最后,我们回顾了关于功能失调的人际行为在SAD中干扰社交功能,特别是亲密和安全关系的发展和维持的作用的研究。我们讨论了MDMA-AT在提高社交技能以引发他人积极人际反应、创造更大的归属感、接受感和社交效能方面的假设作用。